While the translation of preclinical models into viable clinical applications of PI3K/AKT/mTOR inhibition in acute leukemia is only at the early stages, the following sections will give an overview on existing preclinical and clinical data focusing on the most promising concepts (Table 2). Here, PIK3CD is linked to acute leukemia.